Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer
Erasca (ERAS) and Bristol Myers Squibb (BMY) will collaborate on a Phase 1/2 trial to study ERAS-0015 and navlimetostat in MTAP-deleted pancreatic cancer. ERAS-0015 targets RAS, while navlimetostat inhibits PRMT5. Erasca will supply the drug, and BMY will sponsor the study. ERAS stock closed at $13.89, up 3.05% in after-hours trading.


